Get started
Author

Afshin Mashadi-Hossein

Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
2019 · Julia Kargl, Xiaodong Zhu, et al. · JCI Insight · 190
Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System
2009 · Vladislav A Malkov, Kyle A Serikawa, et al. · BMC Research Notes · 161
PDF
Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer
2015 · Tong Li, Yak-Nam Wang, et al. · Cancer Research · 102
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
2019 · Saranya Chumsri, Zhuo Li, et al. · Journal of Clinical Oncology · 80
CD56dim CD16− Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
2019 · Lazar Vujanovic, Christopher Chuckran, et al. · Frontiers in Immunology · 75
PDF
Demonstration of multi-analyte patterning using piezoelectric inkjet printing of multiple layers
2008 · Melissa S. Hasenbank, Thayne Edwards, et al. · Analytica Chimica Acta · 50
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial
2016 · Edith A. Perez, Karla V. Ballman, et al. · JNCI Journal of the National Cancer Institute · 43
PDF
Concentration Gradient Immunoassay. 2. Computational Modeling for Analysis and Optimization
2007 · Jennifer O. Foley, Kjell E. Nelson, et al. · Analytical Chemistry · 39
Experimental and model investigation of the time-dependent 2-dimensional distribution of binding in a herringbone microchannel
2008 · Jennifer O. Foley, Afshin Mashadi-Hossein, et al. · Lab on a Chip · 31
Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma
2020 · Julie Rytlewski, Deepu Madduri, et al. · Blood · 25
Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.
2016 · Brett Wallden, Irena Pekker, et al. · Journal of Clinical Oncology · 18
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
2019 · Saranya Chumsri, Daniel J. Serie, et al. · Clinical Cancer Research · 13
Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System.
2015 · Brett Wallden, Sean Ferree, et al. · Journal of Clinical Oncology · 11
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
2022 · Saranya Chumsri, Zhuo Li, et al. · npj Breast Cancer · 10
PDF
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials.
2018 · Saranya Chumsri, Daniel Serie, et al. · Journal of Clinical Oncology · 8
Development of Gene Expression-Based Biomarkers on the nCounter® Platform for Immuno-Oncology Applications
2019 · Sarah Warren, Patrick Danaher, et al. · Methods in molecular biology · 6
Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31
2019 · S Chumsri, Z Li, et al. · Cancer Research · 6
Gene expression signature development to decode breast cancer heterogeneity.
2018 · Heather Ann Brauer, Afshin Mashadi-Hossein, et al. · Journal of Clinical Oncology · 5
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
2020 · Tenner, Kathleen S., Carr, Jennifer M., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill) · 3
PDF
Statistical Learning Approaches for Predicting Lisocabtagene Maraleucel (liso-cel) Drug Product Composition from Donor-Selected Material Composition
2019 · Yue Jiang, Afshin Mashadi-Hossein, et al. · Blood · 3
Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
2019 · Ethan G. Thompson, Yue Jiang, et al. · Blood · 3
Immune profiling of BRCA-mutated breast cancers.
2018 · Jeremy Meyer Force, Sarah Abbott, et al. · Journal of Clinical Oncology · 3
Genomic profiling of tumors from patients with germline BRCA mutations.
2018 · Anne-Vibeke Laenkholm, Ida Marie Heeholm Soenderstrup, et al. · Journal of Clinical Oncology · 2
Verification of the analytical performance of a molecular diagnostic for response to anti-PD1 therapy on the nCounter Dx Analysis System.
2017 · Brett Wallden, Irena Pekker, et al. · Journal of Clinical Oncology · 2
Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial
2019 · S Chumsri, K Asleh, et al. · Cancer Research · 1
Works count: 70
Citation count: 893
H-index: 12
I10-index: 14
Year
Topic
Type